Annual report pursuant to Section 13 and 15(d)

REVENUES (Details 2)

v3.20.4
REVENUES (Details 2) - Customer Concentration Risk [Member]
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
AmerisourceBergen Specialty Group [Member]    
Entity Wide Revenue Major Customer [Line Items]    
Concentration risk, percentage 58.00% 78.00%
McKesson Plasma and Biologics LLC [Member]    
Entity Wide Revenue Major Customer [Line Items]    
Concentration risk, percentage 23.00% 14.00%
Accounts Receivables [Member] | AmerisourceBergen Specialty Group [Member]    
Entity Wide Revenue Major Customer [Line Items]    
Concentration risk, percentage 56.00% 57.00%
Accounts Receivables [Member] | McKesson Plasma and Biologics LLC [Member]    
Entity Wide Revenue Major Customer [Line Items]    
Concentration risk, percentage 31.00% 25.00%